Cullinan Management (Cullinan Oncology)

General Information
Business:

 

We are a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Our strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that we believe have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. In approximately three-and-a-half years, we have efficiently developed or in-licensed a pipeline of seven distinct programs by leveraging our hub-and-spoke business model. 

(Note: The IPO was upsized to 10 million shares, up from 8.33 million, and the price range was increased to $19 to $20, up from $17 to $19, in an S-1/A filing dated Jan. 6, 2021. The IPO is now expected to raise $195 million, if priced at the $19.50 mid-point of its newly increased range, compared with $149.94 million in estimated proceeds in its initial filing.)

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 17
Founded: 2016
Contact Information
Address One Main Street, Suite 520, Cambridge, MA 02142, US
Phone Number (617) 410-4650
Web Address http://www.cullinanoncology.com
View Prospectus: Cullinan Management (Cullinan Oncology)
Financial Information
Market Cap $680.94mil
Revenues $0 mil (last 12 months)
Net Income $-23.0 mil (last 12 months)
IPO Profile
Symbol CGEM
Exchange NASDAQ
Shares (millions): 11.9
Price range $21.00 - $21.00
Est. $ Volume $249.9 mil
Manager / Joint Managers Morgan Stanley/ SVB Leerink/ Evercore ISI
CO-Managers H.C. Wainwright & Co., LLC
Expected To Trade: 1/8/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change